Invex Therapeutics (ASX:IXC) reported Friday a loss of AU$0.0047 per diluted share for the half year ended Dec. 31, 2024, compared with a loss of AU$0.0281 per diluted share a year earlier.
The company's attributable loss after tax narrowed 83% to AU$356,535 from AU$2.1 million in the year-ago period, the filing said.
The biopharmaceutical company did not declare a dividend during the reported period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.